Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 in Relapsed/Refractory B-CLL
NCT00321724Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2006
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cediranib in chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Primary endpoint: Confirmed Response Rate up to 5 years. Started May 2006; status: completed.
02
Drugs
cediranib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00321724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321724.